Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis

Median Overall Survival Nearly Double than Expected with Standard of Care Alone June 1, 2014 Agenus Inc., announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus’ Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected. In this Phase …

Agenus Vaccine Shows Significant Reduction in Viral Burden after HerpV Generated Immune Activation

Phase 2 trial in patients with genital herpes shows correlation between viral load reduction and CD8 T cell activation, an important clinical surrogate Trial shows booster shot demonstrates sustainable, long-term effect June 23, 2014 Agenus Inc., an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, today announced promising Phase 2 results for …

Ludwig & Agenus to Advance Three Checkpoint Modulator Antibodies

March 5, 2014 Ludwig Cancer Research and Agenus Inc. today announced the selection of three monoclonal antibody checkpoint modulators (CPMs) that Agenus is advancing into preclinical development. These product candidates—two GITR agonists and a CTLA-4 antagonist—target cell-surface checkpoint proteins that control immune responses. They are part of Agenus’ recent acquisition of 4-Antibody AG and the result of several years of intensive collaborative efforts …

Agenus’ individualized brain cancer vaccine generates positive Phase 2 data

No two patients’ cancers are biologically identical, so it makes sense for a therapy to be created individually for each patient. To that end, Agenus’ “individualized” brain cancer vaccine Prophage Series G-200 has generated positive results in a Phase 2 trial, with more than 90% of patients treated with the vaccine alive at 6 months after surgery. Prophage Series vaccines …

Agenus’ brain cancer vaccine impresses in Phase II

US biotech Agenus has announced encouraging results from a Phase II trial of its brain cancer vaccine. Things had taken a turn for the worse for Lexington-based Agenus at the start of the month, as it was announced that a late-stage trial with GSK's MAGE-A3 melanoma cancer vaccine – for which it made the adjuvant – had failed to meet …